

Federica Furfaro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4458735/publications.pdf>

Version: 2024-02-01

94
papers

3,003
citations

218677

26
h-index

182427

51
g-index

94
all docs

94
docs citations

94
times ranked

3395
citing authors

#	ARTICLE	IF	CITATIONS
1	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 4-22.	1.3	741
2	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 155-168.	1.3	478
3	Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2134-2135.	4.4	101
4	Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1385-1391.	1.3	85
5	Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1280-1287.	1.3	79
6	Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease. <i>Gut Microbes</i> , 2019, 10, 149-158.	9.8	70
7	Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1330-1333.	1.3	69
8	Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S678-S686.	1.3	64
9	Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 595-599.	4.1	57
10	Transperineal Perineal Ultrasound Versus Magnetic Resonance Imaging In the Assessment of Perianal Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2737-2743.	1.9	55
11	Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 601-606.	1.9	50
12	Thiopurine treatment in inflammatory bowel disease: Response predictors, safety, and withdrawal in follow-up. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 588-596.	1.3	48
13	MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice. <i>Gastroenterology</i> , 2017, 153, 1363-1377.e6.	1.3	48
14	Point-of-Care Ultrasound in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 143-151.	1.3	46
15	Advanced endoscopic techniques in the assessment of inflammatory bowel disease: new technology, new era. <i>Gut</i> , 2019, 68, 562-572.	12.1	42
16	Maintaining the Quality Standards of Care for Inflammatory Bowel Disease Patients During the COVID-19 Pandemic. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1882-1883.	4.4	40
17	Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1426-1432.e1.	4.4	39
18	Perianal disease is associated with psychiatric co-morbidity in Crohn's disease in remission. <i>International Journal of Colorectal Disease</i> , 2014, 29, 1285-1290.	2.2	36

#	ARTICLE	IF	CITATIONS
19	Glucose intolerance and diabetes mellitus in ulcerative colitis: Pathogenetic and therapeutic implications. <i>World Journal of Gastroenterology</i> , 2014, 20, 3507.	3.3	35
20	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study". <i>Digestive and Liver Disease</i> , 2017, 49, 17-23.	0.9	35
21	Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 417-423.	1.3	35
22	Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation. <i>United European Gastroenterology Journal</i> , 2021, 9, 438-442.	3.8	34
23	Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience. <i>Digestive and Liver Disease</i> , 2017, 49, 872-877.	0.9	33
24	Can IL-23 be a good target for ulcerative colitis?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 95-102.	2.4	31
25	Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 316-322.	1.6	30
26	Predictive Value of Bowel Ultrasound in Crohn's Disease: A 12-Month Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e723-e740.	4.4	30
27	Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1399-1407.	1.9	27
28	Long-term outcome of inflammatory bowel diseases with cytomegalovirus colitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1146-1151.	1.6	26
29	The safety of biological pharmacotherapy for the treatment of ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 437-443.	2.4	24
30	Modulation of sphingosine-1-phosphate in ulcerative colitis. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 413-420.	3.1	24
31	Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. <i>Digestive and Liver Disease</i> , 2022, 54, 440-451.	0.9	22
32	Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 446-454.	3.7	21
33	Biosimilars of adalimumab: the upcoming challenge in IBD. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1023-1030.	3.1	20
34	Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art. <i>Journal of Clinical Medicine</i> , 2022, 11, 939.	2.4	20
35	The impact of symptoms, irritable bowel syndrome pattern and diagnostic investigations on the diagnostic delay of Crohn's disease: A prospective study. <i>Digestive and Liver Disease</i> , 2015, 47, 646-651.	0.9	19
36	Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. <i>Digestive and Liver Disease</i> , 2019, 51, 510-515.	0.9	18

#	ARTICLE	IF	CITATIONS
37	Validation of the Red Flags Index for Early Diagnosis of Crohn's Disease: A Prospective Observational IG-IBD Study Among General Practitioners. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1777-1779.	1.3	18
38	JAK inhibitors: Novel developments in management of ulcerative colitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 89-93.	2.4	17
39	IL-23 Blockade for Crohn's disease: next generation of anti-cytokine therapy. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 457-467.	3.0	16
40	SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 507-516.	17.8	16
41	Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. <i>Digestion</i> , 2017, 96, 166-172.	2.3	15
42	PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 797-806.	3.0	15
43	Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 421-427.	3.1	15
44	Ulcerative colitis: current pharmacotherapy and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1659-1670.	1.8	14
45	Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease - AGED study. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1361-1369.	1.6	14
46	Targeting the gut layers in Crohn's disease: mucosal or transmural healing?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 775-787.	3.0	13
47	Viral infections in inflammatory bowel disease: Tips and tricks for correct management. <i>World Journal of Gastroenterology</i> , 2021, 27, 4276-4297.	3.3	13
48	Overview of Biological Therapy in Ulcerative Colitis: Current and Future Directions. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 203-213.	0.9	13
49	TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease. <i>Current Drug Targets</i> , 2021, 22, 760-769.	2.1	11
50	Rediscovering histology: what is new in endoscopy for inflammatory bowel disease?. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110056.	3.2	11
51	Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 765-773.	3.0	11
52	Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study. <i>United European Gastroenterology Journal</i> , 2022, 10, 190-197.	3.8	11
53	Unrevealed Depression Involves Dysfunctional Coping Strategies in Crohn's Disease Patients in Clinical Remission. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-7.	1.5	9
54	Splanchnic Hemodynamics and Intestinal Vascularity in Crohn's Disease: An In Vivo Evaluation Using Doppler and Contrast-Enhanced Ultrasound and Biochemical Parameters. <i>Ultrasound in Medicine and Biology</i> , 2016, 42, 150-158.	1.5	9

#	ARTICLE	IF	CITATIONS
55	Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?. <i>Current Pharmaceutical Design</i> , 2019, 25, 25-31.	1.9	9
56	The Importance of Disease Prevalence in Assessing the Diagnostic Value of a Test: Endoscopic Markers in Celiac Disease. <i>Digestion</i> , 2013, 87, 254-261.	2.3	8
57	Validation of the "United Registries for Clinical Assessment and Research" [UR-CARE], a European Online Registry for Clinical Care and Research in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 532-537.	1.3	8
58	Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?. <i>Current Pharmaceutical Design</i> , 2019, 25, 7-12.	1.9	8
59	Reproducibility of the electronic chromoendoscopy PICaSSO score (Paddington International Virtual) Tj ETQq1 1 0.784314 rgBT /Overlo multicenter international study (with video). <i>Gastrointestinal Endoscopy</i> , 2022, 96, 73-83.	1.0	8
60	Letter: immunogenicity of infliximab originator vs. CT-EP13 in IBD patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 903-905.	3.7	7
61	Application of Ultrasound Elastography for Assessing Intestinal Fibrosis in Inflammatory Bowel Disease: Fiction or Reality?. <i>Current Drug Targets</i> , 2021, 22, 347-355.	2.1	7
62	Emerging therapeutic targets and strategies in Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 735-744.	3.0	6
63	Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study. <i>Digestive and Liver Disease</i> , 2021, 53, 712-716.	0.9	6
64	Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. <i>Biomedicines</i> , 2022, 10, 843.	3.2	6
65	Early Biological Therapy in Operated Crohn's Disease Patients Is Associated With a Lower Rate of Endoscopic Recurrence and Improved Long-term Outcomes: A Single-center Experience. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 539-547.	1.9	6
66	Gut and mesenteric lymph node involvement in pediatric patients infected with human immunodeficiency virus. <i>HIV/AIDS - Research and Palliative Care</i> , 2014, 6, 69.	0.8	5
67	Bowel Ultrasound in Inflammatory Bowel Disease: How Far in the Grayscale?. <i>Life</i> , 2021, 11, 649.	2.4	5
68	PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 623-629.	4.1	4
69	Detection and management of early stage inflammatory bowel disease: an update for clinicians. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 547-555.	3.0	4
70	Endoscopy after surgery in inflammatory bowel disease: Crohn's disease recurrence and pouch surveillance. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 829-841.	3.0	4
71	Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures. <i>American Journal of Gastroenterology</i> , 2020, 115, 1719-1721.	0.4	4
72	Epidemiological features and disease-related concerns of a large cohort of Italian patients with active Crohn's disease. <i>Digestive and Liver Disease</i> , 2019, 51, 804-811.	0.9	3

#	ARTICLE	IF	CITATIONS
73	Prevention of Postoperative Recurrence in CD: Tailoring Treatment to Patient Profile. <i>Current Drug Targets</i> , 2019, 20, 1327-1338.	2.1	3
74	Artificial Endoscopy and Inflammatory Bowel Disease: Welcome to the Future. <i>Journal of Clinical Medicine</i> , 2022, 11, 569.	2.4	3
75	Cross-Sectional Imaging Instead of Colonoscopy in Inflammatory Bowel Diseases: Lights and Shadows. <i>Journal of Clinical Medicine</i> , 2022, 11, 353.	2.4	3
76	Evolution and New Horizons of Endoscopy in Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2022, 11, 872.	2.4	3
77	Improving quality of care in endoscopy of inflammatory bowel disease: can we do better?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 819-828.	3.0	2
78	JAK inhibitors in crohn's disease: ready to go?. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 145-161.	4.1	2
79	Assessment of the disease extension in children and adolescents with IBD: Comparison of bowel ultrasound and magnetic resonance enterography. <i>Digestive and Liver Disease</i> , 2014, 46, e120.	0.9	1
80	Intestinal gas and liver steatosis: a casual association? A prospective multicentre assessment. <i>Liver International</i> , 2017, 37, 141-147.	3.9	1
81	Psychological Functioning of Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e112-e112.	1.9	1
82	New Paradigms to Help Decisions in Treatment Choice: Head to Head Trial of Biological Therapies in Inflammatory Bowel Diseases. <i>Current Drug Targets</i> , 2021, 22, 370-378.	2.1	1
83	Comparison of two methods for the in-vivo diagnosis of <i>Helicobacter pylori</i> infection using a tablet of ¹³ C-urea. <i>Minerva Gastroenterology</i> , 2017, 63, 319-326.	0.5	1
84	Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Diseases: Chromoendoscopy or Non-Chromoendoscopy, That Is the Question. <i>Journal of Clinical Medicine</i> , 2022, 11, 509.	2.4	1
85	Response Evaluation and Safety of Thiopurines in the Treatment of Inflammatory Bowel Diseases (IBD). <i>Gastroenterology</i> , 2011, 140, S-280-S-281.	1.3	0
86	19 Infliximab Discontinuation Is Associated With a Higher Risk for Relapse in Patients With Ulcerative Colitis in Remission: A Multinational Collaborative Retrospective Study. <i>Gastroenterology</i> , 2016, 150, S6.	1.3	0
87	Mo1987 Accuracy of a New Fujifilm Blue Light Prototype in Predicting the Histology of Subcentimetric Polyps. <i>Gastrointestinal Endoscopy</i> , 2016, 83, AB485.	1.0	0
88	Rapid Detection of Anti-Infliximab Antibodies in Inflammatory Bowel Disease Patients Treated with the Reference Biologic or the Biosimilar CT-P13: Performance Comparison with Elisa. <i>Gastroenterology</i> , 2017, 152, S384.	1.3	0
89	Switching from Infliximab Originator to CT-P13 is not Related to Increased Immunogenicity in IBD Patients: A Prospective Case-Control Study. <i>Gastroenterology</i> , 2017, 152, S384.	1.3	0
90	Antibodies to Infliximab in Patients Treated with Either the Reference Biologic or the Biosimilar CT-P13 Show Identical Reactivity Towards Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2017, 152, S386.	1.3	0

#	ARTICLE	IF	CITATIONS
91	Comparative Accuracy of us Versus MRI and Colonoscopy in Assessing Disease Activity and Complications and Influencing the Decision-Making Process in Crohn's Disease. <i>Gastroenterology</i> , 2017, 152, S66.	1.3	0
92	Stimulation of CYP450-Mediated ω -3 Docosahexaenoic Acid (DHA) Metabolism via MFSD2A as a Novel Therapy for Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2017, 152, S188.	1.3	0
93	Illness Perception in IBD Patients: A Prospective Study. <i>Gastroenterology</i> , 2017, 152, S800.	1.3	0
94	Psychological Challenges for Patients With Inflammatory Bowel Disease During the COVID-19 Pandemic. <i>Psychosomatic Medicine</i> , 2021, 83, 397-398.	2.0	0